D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Total Current Liabilities
ÂĄ448.4m
CAGR 3-Years
63%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Liabilities
ÂĄ1.6B
CAGR 3-Years
27%
CAGR 5-Years
41%
CAGR 10-Years
32%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
32%
CAGR 5-Years
39%
CAGR 10-Years
68%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
448.4m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Total Current Liabilities amounts to 448.4m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
36%

Over the last year, the Total Current Liabilities growth was 80%. The average annual Total Current Liabilities growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 63% over the past three years , 36% over the past five years .

Back to Top